XYNAPSE
LIVE

Serial Number

99446868

Owner

Immudex ApS

Attorney

Miriam D. Trudell

Filing Date

Oct 16, 2025

Add to watchlist:

No watchlists yet
View on USPTO

XYNAPSE Trademark

Serial Number: 99446868

XYNAPSE is a trademark filed by Immudex ApS on October 16, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Immudex ApS (8 trademarks)

Bredevej 2A

Entity Type: 99

Trademark Details

Filing Date

October 16, 2025

Registration Date

Not Registered

Published for Opposition

June 23, 2026

Goods & Services

Chemical products for diagnostic, industrial and scientific purposes, namely reagents and assays for activation, stimulation and proliferation of immune cells T cells and B cells, other than for medical or veterinary use; Diagnostic reagents for diagnostic and scientific purposes, other than for medical or veterinary use; Research reagents for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic test materials in the nature of reagents and assays for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic kits comprising diagnostic agents, preparations and substances for scientific and diagnostic purposes, other than for medical or veterinary use; Assays for research and diagnostic purposes, other than for medical or veterinary use; Biochemical reagents, other than for medical or veterinary use; Analytical preparations in the nature of reagents and assays for scientific purposes related to research and development of vaccines and immunotherapeutics, cancer vaccines, borrelia vaccines, tuberculosis vaccines, HIV vaccines, CMV vaccines and other vaccines, or for use in connection with research and development of drug therapy and immunotherapy, including cancer therapy, cancer immunotherapy, for scientific analysis of pharmaceuticals for T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and for analysis of pharmaceuticals infectious diseases and autoimmunity, and for scientific and research use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring, other than for medical or veterinary use; Chemical reagents for diagnostic, industrial and scientific purposes

Preparations for pharmaceutical purposes, for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Chemical-pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Diagnostic preparations for medical purposes; Reagents for medical and veterinary purposes; Vaccines; Analytical preparations in the nature of assays and reagents for medical purposes, including for the medical or diagnostic analysis of vaccines, immunotherapeutics and cellular therapy, including cancer vaccines and immunotherapeutics, borrelia vaccines, tuberculosis vaccines, HIV vaccines and CMV vaccines, T-cell treatments, or for use in connection with cancer therapy or other therapy, for the diagnosis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and infectious diseases, and for use in connection with medical or diagnostic analysis of toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
May 29, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 28, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 28, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 28, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 11, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 11, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 11, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 4, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 16, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 16, 2025 NWOS
NEW APPLICATION ENTERED
Oct 16, 2025 NWAP